CGRP Prior Authorization Guide: Requirements by Drug and Payer (2025–2026)

Prior authorization for CGRP drugs is one of the most common administrative obstacles neurologists and headache specialists face. This guide covers PA requirements for all FDA-approved CGRP medications across major commercial payers and Medicare — what documentation you need, which step therapy failures qualify, and where payer policies diverge most significantly.

Freshness notice: Payer PA criteria change frequently — often quarterly. The requirements below reflect policies as verified in mid-2025 (UHC policy 2026 P 2146-15, effective 4/1/2026; Cigna CNF331, revised 4/16/2025). Always pull the current published clinical policy PDF from the payer’s provider portal before submitting.

The Gap Between Guidelines and Payer Policy

In 2024, the American Headache Society issued a consensus statement declaring that CGRP-targeting therapies are “a first-line option for the prevention of migraine” and that their use “should not require trial and failure of non-specific migraine preventive medication approaches.” (Headache, 2024;64:333-341)

Most major payers have read this statement, cited it in their clinical policy documents, and then kept step therapy in place anyway.

Understanding this gap — clinical evidence saying first-line, payers requiring prior failures — is the context for everything that follows.

FDA-Approved CGRP Drugs

Preventive Injectable Monoclonal Antibodies

Preventive Oral (Gepants)

Acute Treatment (Gepants)

Vyepti billing note: Eptinezumab is administered as an IV infusion and billed under the medical benefit (like a Part B drug), not the pharmacy benefit. The PA process and coverage pathway are entirely separate from the subcutaneous injectables.

Nurtec ODT dual-indication note: Rimegepant holds two separate FDA approvals. Many payers issue separate PAs for the acute and preventive indications, with different step therapy criteria for each.

Common PA Requirements Across All Payers

1. Diagnosis and Frequency Documentation

Episodic migraine: ≥4 migraine headache days per month (some payers require ≥6 or ≥8), documented over a defined observation period (typically 3 months).

Chronic migraine: ≥15 headache days per month, with ≥8 meeting migraine criteria, over 3 months.

Submit headache diary data or validated outcome measures (MIDAS, HIT-6) alongside the PA. Reviewers should not have to calculate frequency from clinical notes.

UHC-specific thresholds (2026): UHC structures the gate as 4–7 MMDs (with documentation that migraine is the predominant headache diagnosis) OR ≥8 migraine days/month — not simply as episodic vs. chronic labels.

2. Step Therapy — Which Oral Preventives Count

The vast majority of commercial payers still require documented failure of oral preventives before approving a CGRP. The modal requirement is two prior failures (though some regional plans require three, and a growing minority require none).

The qualifying agent classes across payer policies:

“Failure” = adequate trial (typically 6–8 weeks at therapeutic dose) resulting in inadequate efficacy, intolerable side effects, or a documented contraindication.

3. No Combination Therapy Across CGRP Agents

All major payer policies prohibit combining two CGRP-targeting drugs simultaneously for prevention — no Aimovig + Qulipta, no Emgality + Nurtec ODT (preventive dosing). The exclusion applies across both monoclonal antibody and gepant classes. Similarly, no simultaneous Botox + CGRP for chronic migraine on most plans.

4. Specialty Pharmacy Routing

The injectable mAbs (Aimovig, Ajovy, Emgality) require specialty pharmacy dispensing — Accredo, CVS Specialty, AllianceRx Walgreens, or plan-specific networks. Out-of-network specialty pharmacy is one of the most common avoidable denial reasons. Verify the patient’s in-network specialty pharmacy before prescribing.

Vyepti bypasses specialty pharmacy entirely and bills through the medical benefit as an outpatient infusion.

Contraindication Bypass: Waiving Step Therapy

Documented contraindications to required step therapy agents can bypass the requirement.

Critical: Document contraindications explicitly in the clinical notes submitted with the PA — reviewers will not infer them from a medication allergy list or medication history.

Payer-Specific PA Requirements

UnitedHealthcare

Source: UHC Pharmacy Prior Auth/Med Necessity policy 2026 P 2146-15, effective 4/1/2026

Qualifying threshold: ≥4–7 migraine days/month with migraine as the predominant headache diagnosis, OR ≥8 migraine days/month.

Step therapy: Failure after a trial of at least two months, OR documented contraindication or intolerance, to TWO agents from: atenolol, metoprolol, nadolol, propranolol, or timolol (beta-blockers); candesartan; divalproex sodium; onabotulinumtoxinA; duloxetine or venlafaxine (SNRIs); topiramate; amitriptyline or nortriptyline (TCAs).

Specialist requirement: None. UHC removed the prescriber-specialty requirement in 2018.

Authorization duration: 12 months initial; 12 months renewal.

Renewal criteria: Documented positive response — reduction in headache frequency and/or intensity; no concurrent CGRP drug.

State carve-outs (significant):

• California: NO step therapy required (state mandate)
• Connecticut, Kentucky, Mississippi: 30-day trial suffices instead of 2 months

Vyepti: Covered under medical benefit; requires separate PA with infusion center documentation.

Cigna

Source: Cigna National Formulary policy CNF331, revised 4/16/2025 (Aimovig)

Cigna’s national policy for Aimovig is the industry outlier: approval requires only (1) age ≥18 and (2) ≥4 migraine headache days/month. No step therapy required at the national formulary level.

Critical caveat: Cigna is a managed care organization with hundreds of self-funded employer plan customers. Individual employer plan documents CAN add step therapy requirements and supersede the national formulary policy. Always verify the specific patient’s plan document. In practice, the national CNF331 applies to many but not all Cigna-covered lives.

Authorization duration: 1-year initial; renewal requires prescriber-determined “significant clinical benefit” (reduction in migraine days or severe migraine days).

Anti-stacking: No concurrent CGRP agents for prevention.

Aetna

Aetna updates its clinical policy bulletins (CPB) quarterly. The current CGRP CPB requires:

• Episodic migraine (≥4 MMDs) or chronic migraine (≥15 headache days/month with ≥8 migraine days)
• Two prior oral preventive failures (standard list: topiramate, a beta-blocker, TCA, or SNRIs)
• Documented adequate trial duration (typically 6–8 weeks at therapeutic dose)

Aetna strength: Has been receptive to contraindication bypass documentation. Written, explicit contraindication language from the clinician carries significant weight in Aetna’s PA review.

Authorization duration: 6 months initial trending to 12 months; renewal requires response documentation (≥50% reduction in MMDs documented in some Aetna policies).

BlueCross / BCBS

Important: BCBS is a federation of 35+ independent regional plans. PA criteria vary materially between Florida Blue, BCBS of Texas, Anthem, the Federal Employee Program (FEP), and other regional plans. There is no single BCBS CGRP policy.

General pattern (most regional plans):

• Episodic or chronic migraine diagnosis documented
• 2–3 prior oral preventive failures (regional variation is highest here)
• Always pull the specific regional plan’s clinical policy from their provider portal

Federal Employee Program (FEP Blue Medical Policy 5.70.068, Jan 2025):

• Step therapy: 2 failures; generally more standardized than commercial regional plans
• Vyepti covered with PA

Humana

Qualifying diagnoses: Standard episodic/chronic migraine criteria.

Step therapy: 2 prior preventive failures from the standard agent list.

Specialty pharmacy: Humana has aggressive specialty pharmacy channeling. Verify the patient’s in-network specialty pharmacy before submitting — routing to an out-of-network specialty pharmacy is a common avoidable Humana denial.

Humana Medicare Advantage: MA plans have separate criteria and formularies from commercial. Verify via the specific plan benefit document.

Authorization duration: 6 months initial; renewal at 6 months.

Medicare Part D (and Medicare Advantage)

Coverage structure: CGRP preventives are Tier 4–5 (specialty) on most Part D formularies. PA is required on virtually all plans.

Step therapy in Medicare: CMS permits Part D plans to require step therapy for specialty drugs including CGRPs. Most Part D and MA-PD plans require 1–2 prior preventive failures.

Vyepti: Typically covered under Medicare Part B, not Part D, when administered in an outpatient infusion setting. PA goes through the medical benefit.

LIS (Extra Help) patients: Low-Income Subsidy enrollees face $0–$11 copays for covered specialty drugs but remain subject to PA requirements.

IRA 2022: The Inflation Reduction Act authorizes Medicare to negotiate prices for high-spend drugs. CGRP drugs may enter negotiation cycles through 2026–2027.

Chronic Migraine: The Botox Detour

For patients with chronic migraine (≥15 headache days/month), most payers add an additional gatekeeping question: onabotulinumtoxinA (Botox) is separately FDA-approved for chronic migraine prevention. Several payers require either:

1. A trial of Botox before approving a CGRP for chronic migraine, or
2. Documentation of why Botox is not appropriate

If the patient has chronic migraine and hasn’t tried Botox, expect this question from most payers — document proactively why CGRP monotherapy is appropriate or preferred. Cigna and UHC explicitly bar concurrent Botox + CGRP on the same claim.

The Step Therapy Landscape Is Shifting

As of March 2024, approximately 45% of commercial plans/PBMs covered CGRP prevention without step therapy requirements, projected to reach ~60%. Premera removed its prior triptan-trial requirement for CGRP drugs in December 2023 and extended initial approval durations from 6 to 12 months in March 2026.

30+ states have enacted step-therapy reform laws requiring exception pathways — including recently signed legislation in New York. Practical caveat: most state step-therapy laws apply only to fully-insured commercial plans. Self-funded ERISA employer plans — a large share of commercial coverage — are largely exempt from state mandates. The reform trend is real but incomplete.

Tips for First-Pass Approval

These drive the gap between 30%+ denial rates and first-pass approval:

1. State the headache frequency explicitly in the clinical note. “Patient experiences 8 migraine days per month over the past 3 months, documented by headache diary (attached).” Don’t make the reviewer calculate it.

2. Name the step therapy failures with dates, doses, and outcomes. “Topiramate 100 mg daily for 10 weeks — discontinued due to cognitive side effects and <25% reduction in migraine days. Propranolol 80 mg daily for 8 weeks — discontinued due to bradycardia and inadequate response.”

3. Attach headache diary or MIDAS/HIT-6 scores. Objective data reduces appeal rates significantly.

4. If contraindications exist, document them in the clinical note before the PA. They will not be inferred from a medication list.

5. Use payer-specific forms. UHC, Aetna, and Cigna publish drug-specific CGRP PA forms. Using the generic form causes delays.

6. Verify the in-network specialty pharmacy before prescribing.

7. Check your state. California patients covered by UHC require no step therapy at all.

When the First PA Fails: Appeals

Common denial reasons and how to respond:

Peer-to-peer review: Most payer policies entitle patients to a peer-to-peer call between the prescribing neurologist and the payer’s medical director. Peer-to-peer calls have significantly higher overturn rates than written appeals alone — use them for complex denials rather than writing letters.

Sources

Primary payer policies used in this guide:

• UnitedHealthcare Pharmacy PA/Med Necessity — policy 2026 P 2146-15 (eff. 4/1/2026)
• Cigna National Formulary — CNF331, revised 4/16/2025
• FEP Blue Medical Policy 5.70.068 (Jan 2025)
• American Headache Society 2024 Consensus Statement: Headache 2024;64:333-341

PA requirements update frequently. This guide was last reviewed June 2026. Verify current criteria against each payer’s published clinical policy before submitting.

Artificer Health automates prior authorization end-to-end — intake, documentation assembly, electronic submission, and denial appeal — so clinicians stop losing evenings to insurance paperwork. Learn more at artificerhealth.com